Cassava Sciences (SAVA) Price & Analysis

Compare

3,894 Followers

SAVA Stock Chart & Stats

$4.41

-$0.22(-7.28%)

At close: Jan 08 4:00 PM EST

$4.41

-$0.22(-7.28%)

Day’s Range― - ―

52-Week Range$1.15 - $33.98

Previous CloseN/A

Volume2.36M

Average Volume (3M)2.85M

Market Cap

$142.99M

Enterprise ValueN/A

Total Cash (Recent Filing)$112.38M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Dec 13, 2012

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding48,307,896

10 Day Avg. Volume1,465,286

30 Day Avg. Volume2,849,288

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.00

Price Target Upside81.41% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market DemandThere is an unmet medical need for anti-seizure treatment options, suggesting potential demand for new solutions like simufilam.

New OpportunitiesThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.

Bears Say

Clinical TrialsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.

Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.

Cassava Sciences News

Cassava Sciences appoints Dawn Bir to board of directors

Cassava Sciences (SAVA) announced the appointment of Dawn Bir to its Board of Directors. Dawn Bir is a...

15d ago

SAVA

Cassava Sciences’ Legal Victory Clears Research Path

The latest announcement is out from Cassava Sciences ( ($SAVA) ). On October 23, 2025, the United States...

13d ago

SAVA

Cassava Sciences Appoints Dawn C. Bir to Board

The latest announcement is out from Cassava Sciences ( ($SAVA) ). On October 22, 2025, Cassava Sciences announced...

15d ago

SAVA

Cassava Sciences initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Cassava Sciences (SAVA) with a Buy rating and $8 price target Cassava is...

1M ago

SAVA

Insider Moves: Cassava, Lithium Americas, EOG, Seagate, Pure Storage

Insiders have been trading these 5 stocks: (($SAVA)), (($TSE:LAC)), (($EOG)), (($STX)) and (($PSTG)). Here is a breakdown of...

1M ago

EOG

LAC

Cassava, Celestica, Gitlab, Pure, Stag: Stock Moves

Insiders have been trading these 5 stocks: (($SAVA)), (($TSE:CLS)), (($GTLB)), (($PSTG)) and (($STAG)). Here is a breakdown of...

1M ago

CLS

GTLB

Cassava Sciences (SAVA) Insider Trade Alert! CEO Richard Barry Buys Stock

Cassava Sciences ($SAVA) CEO Richard Barry bought 237,941 shares at prices ranging between $2.13-$2.29 per share, totaling $534,743....

1M ago

SAVA

Cassava Sciences Releases New Corporate Presentation

Cassava Sciences ( ($SAVA) ) has shared an update. Cassava Sciences, Inc. has released a corporate presentation available...

2M ago

SAVA

Cassava Sciences Advances Simufilam for Epilepsy Treatment

Cassava Sciences ( ($SAVA) ) has released its Q2 earnings. Here is a breakdown of the information Cassava...

3M ago

SAVA

Cassava Sciences reports Q2 EPS (92c) vs 13c last year

“2025 has been transformational for Cassava. We have initiated a new program focused on TSC-related epilepsy, a rare...

3M ago

SAVA

Cassava Sciences appoints Hulihan as Chief Medical Officer

Cassava Sciences (SAVA) announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer, CMO. Dr. Hulihan will...

3M ago

SAVA

Cassava Sciences Announces Positive Preclinical Results

Cassava Sciences ( ($SAVA) ) has issued an announcement. On August 4, 2025, Cassava Sciences announced positive preclinical...

3M ago

SAVA

Cassava reports preclinical study on simufilam for TSC-related epilepsy

Cassava Sciences (SAVA) reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of...

3M ago

SAVA

Cassava Sciences Reveals Promising Simufilam Preclinical Data

The latest update is out from Cassava Sciences ( ($SAVA) ). On June 30, 2025, Cassava Sciences announced...

4M ago

SAVA

SAVA FAQ

What was Cassava Sciences’s price range in the past 12 months?

Cassava Sciences lowest stock price was $1.15 and its highest was $33.98 in the past 12 months.

What is Cassava Sciences’s market cap?

Cassava Sciences’s market cap is $142.99M.

When is Cassava Sciences’s upcoming earnings report date?

Cassava Sciences’s upcoming earnings report date is Mar 03, 2026 which is in 117 days.

How were Cassava Sciences’s earnings last quarter?

Currently, no data Available

Is Cassava Sciences overvalued?

According to Wall Street analysts Cassava Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cassava Sciences pay dividends?

Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here

What is Cassava Sciences’s EPS estimate?

Cassava Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cassava Sciences have?

Cassava Sciences has 48,307,896 shares outstanding.

What happened to Cassava Sciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Cassava Sciences?

Currently, no hedge funds are holding shares in SAVA

Cassava Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-88.95%

Trailing 12-Months

Asset Growth

-44.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cassava Sciences

Cassava Sciences, Inc. (SAVA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company's primary focus is on Alzheimer's disease, with its lead therapeutic product candidate, Simufilam, designed to improve cognitive function in patients. Cassava Sciences also engages in developing diagnostic products for detecting Alzheimer's disease.

Cassava Sciences (SAVA) Earnings & Revenues

Historic Earnings Reports

SAVA Stock 12 Month Forecast

Average Price Target

$8.00

▲(81.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","21":"$21","28":"$28"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7,14,21,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.2,3.5692307692307694,3.9384615384615387,4.3076923076923075,4.676923076923077,5.046153846153846,5.415384615384616,5.7846153846153845,6.153846153846153,6.523076923076923,6.892307692307693,7.2615384615384615,7.63076923076923,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.2,3.5692307692307694,3.9384615384615387,4.3076923076923075,4.676923076923077,5.046153846153846,5.415384615384616,5.7846153846153845,6.153846153846153,6.523076923076923,6.892307692307693,7.2615384615384615,7.63076923076923,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.2,3.5692307692307694,3.9384615384615387,4.3076923076923075,4.676923076923077,5.046153846153846,5.415384615384616,5.7846153846153845,6.153846153846153,6.523076923076923,6.892307692307693,7.2615384615384615,7.63076923076923,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.14,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.21,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >